Triple-negative breast cancers (TNBCs) represent 15% of all breast cancers (BCs) and are defined by the absence of estrogen receptors (ERs), progesterone receptors (PRs), and Growth Factor Receptor-2 (HER2) overexpression/amplification [1,2]. This evidence concerns the gene ERBB2 and breast cancer.